Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial
Brian Rayner, Kenneth W Mahaffey, Johannes F E Mann, Richard E Pratley, Peter Rossing, Nicolas Belmar, Heidrun Bosch-Traberg, Ole Kleist Jeppesen, Minh Chau Tran, Gil Chernin, Katherine R Tuttle · 2026
Read Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial by Brian Rayner, Kenneth W Mahaffey, Johannes F E Mann, Richard E Pratley, Peter Rossing, Nicolas Belmar, Heidrun Bosch-Traberg, Ole Kleist Jeppesen, Minh Chau Tran, Gil Chernin, Katherine R Tuttle (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13518088.txt.
Description
Rayner and colleagues analyzed infection outcomes in 2026 from the FLOW trial of once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. The main trial had shown the drug cuts kidney, heart, and death outcomes in this group, who also suffer heavy infection burdens. This prespecified analysis asked whether serious infections, hospitalizations for infection, and COVID-19 events also fell on the drug.
Semaglutide lowered the combined risk of a first serious infection event, infection hospitalization, or death by about a fifth against placebo. Infection serious events, COVID-19 events, and infection hospitalizations each ran lower on the drug. The benefit was larger in patients who started with poorer blood sugar control and in those with the heaviest urine protein, markers of higher risk. The authors say the drug's value in this population may extend beyond its proven kidney and heart gains.
Catalog record
| CREATOR | Brian Rayner, Kenneth W Mahaffey, Johannes F E Mann, Richard E Pratley, Peter Rossing, Nicolas Belmar, Heidrun Bosch-Traberg, Ole Kleist Jeppesen, Minh Chau Tran, Gil Chernin, Katherine R Tuttle |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |